Intrauterine growth restriction. Disorders of newborn related to slow fetal growth and fetal malnutrition
Conditions
Interventions
Intervention 1: Group A (sildenafil): In this group, sildenafil citrate tablets (Vizarcin), 25 mg orally every eight hours for four weeks. Intervention 2: Group B (Melatonin): In this group, melatonin
Sponsors
Yasouj University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Single-pregnancy pregnancy with IUGR Pregnancy's age between 26 and 32 weeks Mother's age between 18 to 45 years No using alcohol and cigarettes Normal anomaly scan The absence of fetal with known or suspected anomalies No gestational or chronic diagnosed diabetes Not using other vasodilator drugs such as nitric oxide and calcium channel blockers
Exclusion criteria
Exclusion criteria: Lack of follow-up Unwillingness to participate in the study Complications such as premature rupture of membrane, vaginal bleeding, and intrauterine infection Sildenafil sensitivity and tolerance to side effects (flushing, visual disturbances, severe drop in blood pressure and hearing impairment)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight percentile. Timepoint: At each visit pregnancy. Method of measurement: Ultrasound.;Abdominal circumference growth. Timepoint: At each visit pregnancy. Method of measurement: Ultrasound.;Fetal amniotic fluid index. Timepoint: At each visit pregnancy. Method of measurement: Ultrasound.;Pregnancy duration. Timepoint: End of pregnancy. Method of measurement: Questionnaire.;Neonate anthropometric measurements (height and weight). Timepoint: Delivery time. Method of measurement: Scales and meters.;Quality of life. Timepoint: End of intervention. Method of measurement: Questionnaire.;Sleep quality. Timepoint: End of intervention. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShakiba Amirjani
Yasouj University of Medical Sciences
Outcome results
None listed